Education
About Us
Working with TipRanks
Follow Us
Zealand Pharma (ZLDPF)
OTHER OTC:ZLDPF
Earnings Data
Report Date
Aug 14, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
14.46Last Year’s EPS
-0.7Same Quarter Last Year
Strong Buy
Based on 6 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 08, 2025
|% Change Since: 4.37%
|Next Earnings Date:Aug 14, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted Zealand Pharma's strong financial position and strategic partnership with Roche, which are expected to drive future growth and pipeline expansion. However, the company faces challenges due to geopolitical and market uncertainty and regulatory hurdles for Dasiglucagon.Company Guidance
During the call, Zealand Pharma provided comprehensive guidance on its financial and operational outlook for the upcoming period. The company reported revenue of DKK8 million for the first quarter of 2025, largely due to a license agreement with Novo Nordisk. They anticipate a substantial boost in their cash position with an expected US$1.4 billion upfront payment from the Roche collaboration, which will bring their cash reserves to approximately DKK 18 billion. This partnership with Roche includes a 50/50 profit-sharing agreement in the US and Europe for their obesity drug candidate, petrelintide. Zealand Pharma expects to leverage this financial strength to reach profitability without needing additional capital. They have reaffirmed their financial guidance for 2025, projecting net operating expenses between DKK 2 billion and DKK 2.5 billion, excluding transaction costs related to the Roche deal. The company is focusing on the development of its clinical pipeline, including the petrelintide Phase 2 ZUPREME program and other obesity and rare disease programs, with major milestones expected in 2026.Strategic Partnership with Roche
Zealand Pharma entered a transformative collaboration with Roche on petrelintide, which includes co-development and co-commercialization rights, and a 50/50 profit sharing in the US and Europe.
Strong Financial Position
Zealand Pharma has secured enough capital to fund its journey towards profitability, with cash, cash equivalents, and marketable securities totaling DKK 8.5 billion as of March 31, 2025.
Future Growth and Pipeline Expansion
The company plans significant new investments in its research pipeline targeting obesity and inflammation, supported by the Roche partnership.
Successful Enrollment in ZUPREME-1 Trial
Zealand Pharma completed enrollment for the Phase 2 ZUPREME-1 trial in March 2025, just three months after initiation.
Phase 3 Program for Survodutide
Boehringer Ingelheim completed enrollment in the Phase 3 synchronized cardiovascular outcomes trial for survodutide, which holds best-in-class potential for obesity and MASH treatment.
ZLDPF Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
ZLDPF Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 08, 2025 | $68.22 | $63.26 | -7.27% |
Feb 20, 2025 | $108.08 | $106.34 | -1.61% |
Nov 07, 2024 | $125.31 | $119.04 | -5.00% |
Aug 15, 2024 | $137.00 | $136.99 | >-0.01% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Zealand Pharma (ZLDPF) report earnings?
Zealand Pharma (ZLDPF) is schdueled to report earning on Aug 14, 2025, TBA Not Confirmed.
What is Zealand Pharma (ZLDPF) earnings time?
Zealand Pharma (ZLDPF) earnings time is at Aug 14, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ZLDPF EPS forecast?
ZLDPF EPS forecast for the fiscal quarter 2025 (Q2) is 14.46.